Compare AXSM & UHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXSM | UHS |
|---|---|---|
| Founded | 2012 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 10.2B |
| IPO Year | 2015 | 1994 |
| Metric | AXSM | UHS |
|---|---|---|
| Price | $214.07 | $170.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 11 |
| Target Price | $211.12 | ★ $216.36 |
| AVG Volume (30 Days) | 706.7K | ★ 896.5K |
| Earning Date | 05-04-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 0.48% |
| EPS Growth | ★ 38.56 | 37.34 |
| EPS | N/A | ★ 11.63 |
| Revenue | N/A | ★ $17,364,829,000.00 |
| Revenue This Year | $57.24 | $7.67 |
| Revenue Next Year | $55.88 | $4.99 |
| P/E Ratio | ★ N/A | $14.72 |
| Revenue Growth | N/A | ★ 9.71 |
| 52 Week Low | $109.40 | $140.08 |
| 52 Week High | $260.19 | $246.33 |
| Indicator | AXSM | UHS |
|---|---|---|
| Relative Strength Index (RSI) | 41.14 | 59.78 |
| Support Level | $206.94 | $142.45 |
| Resistance Level | $236.26 | $175.51 |
| Average True Range (ATR) | 8.99 | 6.55 |
| MACD | -0.49 | 0.19 |
| Stochastic Oscillator | 21.76 | 79.05 |
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Universal Health Services Inc offers healthcare services through its behavioral health centers, acute care hospitals, and related outpatient facilities. As of late 2025, the company operated 346 inpatient behavioral health centers, 29 acute care hospitals, and many supportive outpatient facilities. Its operations are concentrated in the U.S, particularly in Nevada (21% of 2025 operating profits), Texas (19%), and California (13%), although it does have some exposure to the UK behavioral health market (6% of 2025 sales) too. While its acute care services account for over 55% of revenue, the behavioral health centers sport higher margins and account for over 55% of pretax profits.